FGD2 and myalgic encephalomeyelitis/chronic fatigue syndrome: The promoter site associated with FGD2 that was hypermethylated only in the LC patients compared with the HC increased from 52% to 81% whereas it was unchanged at 50% in the ME/CFS cohort.